News & Events – Sumitovant

Select Company

October 08, 2021Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
August 26, 2021Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
August 04, 2021Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
May 03, 2021Aceragen Launches with Acquisition of Enzyvant‘s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
April 27, 2021ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
December 27, 2019Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance
October 16, 2019Enzyvant Appoints Jeb Ledell as Chief Operating Officer
June 05, 2019Enzyvant Announces FDA Acceptance of Biologics License Application (BLA) and Priority Review Status for RVT-802, a Novel Investigational Tissue-Based Regenerative Therapy for Pediatric Congenital Athymia
March 21, 2019Enzyvant’s Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
February 21, 2019Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
1 2 Next »